查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840788

合成生物学市场（按产品、技术、应用和最终用户划分）—2025-2032 年全球预测

Synthetic Biology Market by Product, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年合成生物市场规模将成长至 481.8 亿美元，复合年增长率为 17.04%。

主要市场统计数据
基准年2024年 136.7亿美元
预计2025年 158亿美元
预测年份：2032年 481.8亿美元
复合年增长率（%） 17.04%

简洁而策略性地说明合成生物学的跨学科创新及其对商业和科学领导者的战略意义

本执行摘要介绍了合成生物学这个跨学科领域，它正在重塑生物系统的设计、工程和商业化规模化。引言将合成生物学置于运算设计、精密工程和湿实验室创新融合的时代背景下，为农业、工业製造、环境应用和生命科学领域带来新的产品和服务。透过探讨技术力和市场动态，本文强调了决策者应优先关注和投资的领域。

本章阐述了合成生物学为企业带来的核心价值：透过自动化模组化设计加速产品开发週期，透过标准化生物组件来提高可重复性，以及随着合成生物学取代传统化学和农业流程而带来的下游成本优势。本章也重点介绍了软体开发商、设备製造商和服务供应商如何伙伴关係，打造一个能够实现先进生物工程商业性化的生态系统。引言部分概述了后续分析的结构，并重点介绍了后续章节，这些章节探讨了变革性转变、政策影响、细分考虑、区域动态、竞争定位、领导者建议、研究方法以及支持战略决策的结论和背景。

自动化、竞争性设计和先进基因组学的快速整合如何重塑竞争优势并加速跨产业的产品创新

合成生物学正在经历变革性的转变，这种转变超越了渐进式的技术改进，并从根本上改变了产品的构思、设计和交付方式。其中最重要的转变之一是计算设计工具与实验室自动化的日益整合，将「设计-建造-测试-学习」的週期从数月缩短至数週。这种融合使团队能够快速迭代基因构建体、代谢途径和合成底盘，从而催生新的产品类别。

同时，从DNA合成仪、新一代定序仪到可程式生物反应器等模组化硬体平台的日趋成熟，催生了标准化接口，加速了不同供应商和实验室之间的互通性。随着仪器越来越普及，软体也越来越复杂，分散式研究模式正在兴起，分散的团队在共用设计库和远端执行平台上进行协作。这种去中心化模式也改变了人才格局，推动了对能够连接计算和生物学专业知识的专家以及能够提供端到端计划执行的服务供应商的需求。

另一个变革轴心是先进基因组编辑和合成基因组学技术的兴起，它们扩大了可能的生物功能范围。 CRISPR 衍生工具以及高通量基因合成和自动化组装方法的广泛应用，使得诸如路径优化和底盘最小化等复杂的工程任务能够以以前无法实现的规模完成。这些技术变革与不断变化的监管互动和日益严格的公众监督同步发生，迫使组织采用更强有力的管治框架和透明的传播策略。总之，这些变化正在重塑竞争优势，有利于那些能够结合平台规模研发、多学科人才和严格管治来建立可重复产品开发流程的公司。

评估近期关税变化如何重塑采购、製造和筹资策略

美国近期的贸易政策变化和关税调整，为依赖跨境供应链采购仪器、耗材和专用试剂的公司带来了新的成本考量。关税的累积影响在整个价值链上呈现不均衡的态势，而定序仪和合成器等资本设备的进口关税高于模组化软体和本地服务。这种不对称奖励企业重新评估筹资策略，加快某些製造流程的在地化，并在受影响较小的地区寻找替代供应商。

为了应对这项挑战，采购团队和研发负责人正在采取一系列短期和中期策略。短期因应措施包括重新协商供应合约、增加关键任务耗材的安全库存，以及利用合约研究机构来弥补产能限制。中期而言，企业正在考虑投资区域高价值零件製造中心，并建立伙伴关係，将知识转移给本地製造合作伙伴。决策者正在权衡确保供应链韧性的需求与从创新专案转移资金的机会成本。

同时，关税主导的成本压力正推动仪器製造商和试剂供应商加强合作，以打造价格和交付更可预测的捆绑解决方案。这种商业性结构降低了交易复杂性，并帮助最终用户管理整体拥有成本。政策波动也凸显了情境规划和压力测试采购模型的重要性。那些拥有多元化采购管道、建立关键物资策略储备并积极与政策顾问沟通的机构，将更有能力保持研究的连续性并减轻商业性中断的影响。

多方面的細項分析揭示了产品、技术、应用和最终用户向量如何融合以形成采用路径和商业化策略

深入的细分能够揭示价值创造的领域、能力的聚集方式以及商业化的路径。在耗材和试剂领域，酵素和蛋白质、套件和试剂盒、培养基和补充剂代表不同的购买行为和生命週期需求；而设备则包括生物资讯工作站、PCR仪、定序仪和合成仪，用于支援实验室产能和资本规划。此产品视角阐明了一次性资本支出和经常性试剂成本在采购週期上的差异，为策略伙伴关係关係和定价模型提供参考。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 利用基于 CRISPR 的基因迴路开发针对固态肿瘤的可程式设计细胞疗法
  • 扩大微生物发酵规模，实现高价值生物基化学品的工业规模永续生产
  • 整合人工智慧驱动设计与机器学习，加速微生物生物合成途径优化
  • 采用无细胞平台进行快速原型製作和按需生物製造治疗剂
  • 模组化蛋白质支架在代谢工程中用于精确酵素共定位的进展
  • 合成生物产品监管环境的不断变化将加快主要市场的核准
  • 生物防护策略投资激增，以解决基因改造生物在环境中释放的安全问题
  • 改善质地并提高成本竞争力的合成生物培养肉产品的商业化
  • 开发整合机器人技术和高通量分析的晶圆代工厂，实现自动化应变工程工作流程
  • 合成最小细胞作为客製化生物感测和环境修復的多功能底盘的出现

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章合成生物学市场：依产品

  • 耗材和试剂
    • 酵素和蛋白质
    • 套件和检测试剂
    • 媒体和补充资料
  • 装置
    • 生物资讯工作站
    • PCR仪
    • 序列器
    • 合成器
  • 服务
  • 软体

第九章合成生物学市场：依技术

  • 生物资讯学工具
    • 资料管理
    • 设计自动化
    • 序列分析
  • 细胞工程
    • 细胞株开发
    • 合成细胞设计
  • 基因合成
    • DNA列印
    • 基因组组装
    • 寡核苷酸合成
  • 基因组编辑
    • CRISPR Cas
    • Meganucleases
  • 合成基因组学
    • 最小细胞
    • 外来生物学

第 10 章合成生物学市场：按应用

  • 农业
    • 基因改造作物
    • 合成肥料
  • 环境
    • 生物修復
    • 碳捕获
    • 废弃物处理
  • 产业
    • 生物催化剂
    • 生质燃料
    • 生质塑胶和生物聚合物
    • 特种化学品
  • 生命科学
    • 药物研发
    • 基因治疗
    • 个人化医疗
    • 疫苗研发

第 11 章。合成生物学市场（按最终用户）

  • 学术研究机构
  • 农业和食品公司
  • 合约研究组织
  • 製药和生物技术公司

第 12 章。按地区分類的合成生物学市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章合成生物学市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按国家/地区分類的合成生物学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • Amyris, Inc.
    • Arzeda
    • Batavia Biosciences BV
    • Beam Therapeutics
    • Beckman Coulter, Inc. by Danaher Corporation
    • BGI Genomics Co., Ltd.
    • Codexis, Inc.
    • Conagen, Inc.
    • Creative Enzymes
    • DNA TwoPointO Inc.
    • Editas Medicine, Inc.
    • Eurofins Scientific SE
    • GenScript Biotech Corporation
    • Ginkgo Bioworks, Inc.
    • Integrated DNA Technologies, Inc.
    • Merck KGaA
    • New England Biolabs GmbH
    • Novozymes A/S
    • Precigen, Inc.
    • QIAGEN NV
    • Sangamo Therapeutics
    • Scarab Genomics, LLC
    • Synlogic
    • Synthego Corporation
    • TeselaGen Service
    • Thermo Fisher Scientific Inc.
    • Twist Bioscience Corporation
Product Code: MRR-B9334AD6BE33

The Synthetic Biology Market is projected to grow by USD 48.18 billion at a CAGR of 17.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.67 billion
Estimated Year [2025] USD 15.80 billion
Forecast Year [2032] USD 48.18 billion
CAGR (%) 17.04%

A concise and strategic orientation that frames synthetic biology's multidisciplinary innovations and their strategic implications for commercial and scientific leaders

This executive summary introduces synthetic biology as a fundamentally interdisciplinary field that is reshaping how biological systems are designed, engineered, and scaled for commercial use. The introduction situates synthetic biology within a landscape where computational design, precision engineering, and wet-lab innovation converge to enable new classes of products and services across agriculture, industrial manufacturing, environmental applications, and life sciences. By framing the discussion around both technological capability and market adoption dynamics, the narrative emphasizes where decision-makers should prioritize attention and investment.

The section proceeds by articulating the core value propositions that synthetic biology unlocks for organizations: accelerated product development cycles through modular design automation, enhanced reproducibility via standardized biological parts, and downstream cost advantages where engineered biology displaces traditional chemical or agricultural processes. It further highlights how partnerships between software developers, instrument manufacturers, and service providers form the ecosystem that makes advanced biological engineering commercially tractable. The introduction closes by outlining the structure of the analysis to follow, clarifying that subsequent sections will examine transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive positioning, recommendations for leaders, research methods, and conclusive context to support strategic decisions.

How rapid integration of automation, computational design, and advanced genomics is rewriting competitive advantage and accelerating product innovation across sectors

Synthetic biology is experiencing transformative shifts that extend beyond incremental technological improvements to fundamental changes in how products are conceived, designed, and delivered. One of the most consequential shifts is the increasing integration of computational design tools with lab automation, enabling design-build-test-learn cycles to compress from months to weeks. This convergence is unlocking new product classes by allowing teams to iterate rapidly on genetic constructs, metabolic pathways, and synthetic chassis, while also reducing the barriers to entry for organizations without deep wet-lab heritage.

Concurrently, the maturation of modular hardware platforms-ranging from DNA synthesizers and next-generation sequencers to programmable bioreactors-has created standardized interfaces that accelerate interoperability across vendors and labs. As instruments become more accessible and software becomes more sophisticated, a decentralized research model is emerging in which distributed teams can collaborate on shared design repositories and remote execution platforms. This distribution is altering talent dynamics, with demand shifting toward professionals who bridge computational and biological expertise and toward service providers who can deliver end-to-end project execution.

Another axis of transformation is the rise of advanced genome editing and synthetic genomics techniques, which broaden the palette of achievable biological functions. The diffusion of CRISPR-derived tools alongside high-throughput gene synthesis and automated assembly methods is enabling complex engineering tasks such as pathway optimization and chassis minimization at scales that were previously impractical. These technological shifts are paralleled by evolving regulatory conversations and increasing public scrutiny, prompting organizations to adopt more robust governance frameworks and transparent communication strategies. Taken together, these transformations are reshaping competitive advantage to favor entities that can combine platform-scale R&D, cross-disciplinary talent, and disciplined governance into repeatable product development processes.

Assessing how recent tariff shifts have reconfigured sourcing, manufacturing, and procurement strategies with tangible implications for resilience and product delivery timelines

Recent trade policy developments and tariff adjustments in the United States have introduced new cost considerations for companies that rely on cross-border supply chains for instruments, consumables, and specialized reagents. The cumulative impact of tariffs has been felt unevenly across the value chain, with capital equipment such as sequencers and synthesizers bearing higher exposure to import duties relative to modular software and local services. This asymmetry has created incentives for organizations to reassess sourcing strategies, accelerate localization of certain manufacturing processes, and explore alternative suppliers in less affected jurisdictions.

In response, procurement teams and R&D leaders have adopted a mix of short- and medium-term tactics. Short-term responses include renegotiating supply contracts, increasing safety stock of mission-critical consumables, and leveraging contract research organizations to bridge capacity constraints. Over the medium term, companies are contemplating investments in regionalized manufacturing hubs for high-value components and building partnerships that transfer knowledge to local production partners. These shifts are changing the calculus for capital allocation: decision-makers are balancing the need to secure resilient supply chains against the opportunity costs of diverting funds from innovation programs.

At the same time, tariff-driven cost pressures have heightened collaboration between instrument manufacturers and reagent suppliers to create bundled solutions that can be priced and shipped more predictably. Such commercial constructs reduce transactional complexity and help end users manage total cost of ownership. Policy volatility has also elevated the importance of scenario planning and stress-testing of procurement models. Organizations that maintain diversified sourcing, cultivate strategic stockpiles for critical items, and engage proactively with policy advisors will be better positioned to sustain research continuity and mitigate commercial disruption.

Multidimensional segmentation analysis revealing how product, technology, application, and end-user vectors converge to shape adoption pathways and commercialization strategies

Insightful segmentation reveals where value is created, how capabilities cluster, and which pathways lead to commercialization. Based on product, the market spans consumables and reagents, instruments, services, and software; within consumables and reagents, enzymes and proteins, kits and assays, and media and supplements represent distinct purchasing behaviors and lifecycle needs, while instruments encompass bioinformatics workstations, PCR machines, sequencers, and synthesizers that anchor lab capabilities and capital planning. This product lens clarifies how purchasing cycles differ between one-time capital investments and recurring reagent spend, informing strategic partnerships and pricing models.

Based on technology, the landscape is organized around bioinformatics tools, cell engineering, gene synthesis, genome editing, and synthetic genomics; bioinformatics tools further decompose into data management, design automation, and sequence analysis, whereas cell engineering splits into cell line development and synthetic cell design. Gene synthesis breaks down into DNA printing, gene assembly, and oligonucleotide synthesis, while genome editing separates into CRISPR Cas technologies and meganucleases; synthetic genomics includes approaches such as minimal cell design and xenobiology. This technology-based segmentation highlights where R&D investments concentrate and which platform capabilities will be foundational for next-generation products.

Based on application, the field extends across agriculture, environmental, industrial, and life sciences; within agriculture, genetically modified crops and synthetic fertilizers point to agronomic productivity and input optimization, while environmental use cases-bioremediation, carbon capture, and waste treatment-underscore sustainability-focused deployments. Industrial applications include biocatalysts, biofuels, bioplastics and biopolymers, and specialty chemicals, each with distinct scale-up and regulatory paths, and life sciences applications encompass drug discovery, gene therapy, personalized medicine, and vaccine development, where clinical validation and regulatory clearance shape timelines. Finally, based on end user, the market is organized around academic and research institutes, agriculture and food companies, contract research organizations, and pharmaceutical and biotechnology companies, each with unique procurement governance, adoption velocity, and partnership models. Together, these segmentation perspectives form a multidimensional map that leaders can use to align product roadmaps, go-to-market strategies, and partnership priorities with distinct user needs and technology maturities.

Comparative regional dynamics and strategic implications illustrating how regulatory regimes, manufacturing capacity, and funding ecosystems influence adoption across global markets

Regional dynamics materially influence how technologies are adopted, regulated, and commercialized, and a comparative view across the Americas, Europe Middle East and Africa, and Asia-Pacific highlights differentiated priorities and strengths. In the Americas, innovation ecosystems anchored by strong venture capital networks and advanced research institutions tend to accelerate translational activity and early-stage commercialization, with particular strength in life sciences applications and synthetic biology platforms that support therapeutics and diagnostics. This region's regulatory environment and proximity to large biotech clusters also support rapid iterations between research and market-entry activities.

Across Europe, Middle East and Africa, policy frameworks and public funding instruments emphasize biosecurity, ethical governance, and sustainability, which influence the development of environmental and industrial applications. Collaboration between national research centers and industry consortia is common, and regulatory stringency often shapes product design choices, particularly for agricultural and environmental deployments. In the Asia-Pacific region, manufacturing scale, cost-competitive production capacity, and rapidly growing domestic markets create opportunities for scaling upstream production of reagents and instruments as well as for industrial biotech applications such as bioplastics, specialty chemicals, and biofuels. Local regulatory regimes and national industrial strategies in this region can accelerate adoption where alignment exists between government priorities and private-sector investment. Recognizing these regional differentials enables more effective market entry sequencing, supply chain decisions, and talent recruitment strategies that reflect local strengths and constraints.

Competitive landscape insights highlighting why platform integration, specialist innovation, and strategic partnerships determine who scales successfully in synthetic biology markets

Competitive positioning within synthetic biology is shaped by companies that combine platform technologies, deep application expertise, and integrated service offerings. Leading firms prioritize vertical integration across design tools, instruments, and services to capture more of the value chain and to reduce friction for end users. These integrated players often invest heavily in proprietary data assets and workflow automation, enabling them to shorten development cycles and to offer higher levels of reproducibility and scalability than more narrowly focused rivals.

At the same time, specialist companies that focus on a single segment-such as high-precision DNA synthesis, novel enzyme production, or design automation software-retain strategic importance because they drive technical innovation and create partnership opportunities for platform providers. Contract research organizations and service providers play a critical role in de-risking early-stage projects and in enabling companies without large internal labs to access advanced capabilities. Partnerships between instrument manufacturers and reagent suppliers are increasingly common as a means to create turnkey solutions that reduce adoption friction for end users.

Investor attention and strategic partnerships are frequently directed toward firms that demonstrate clear pathways to regulatory readiness, strong intellectual property positions, and defensible data moats. Organizations that can articulate robust safety and governance models alongside compelling technical performance are better positioned to win public trust and to accelerate commercialization. Ultimately, competitive differentiation increasingly depends on the ability to translate technical capability into repeatable commercial processes that customers can deploy reliably at scale.

Actionable strategic priorities for leaders to align infrastructure, governance, talent, and partnerships to accelerate commercialization while managing regulatory and supply risks

Industry leaders should prioritize a set of actionable measures that align technological capability with commercial imperatives and regulatory realities. First, invest in modular infrastructure that supports rapid iteration: adopt interoperable instruments, standardize data formats, and implement laboratory automation to compress development timelines and reduce error rates. These investments not only speed innovation but also create operational leverage as product portfolios expand. Second, develop supply chain resilience by diversifying supplier relationships, evaluating regional production partnerships, and negotiating flexible contracts to mitigate tariff and logistics volatility. Proactive procurement planning reduces downtime and preserves R&D momentum.

Third, adopt robust governance and stakeholder engagement strategies that transparently address biosafety, biosecurity, and ethical considerations. Clear communication and third-party validation of safety frameworks will be essential for building public trust and for smoothing regulatory interactions. Fourth, cultivate cross-disciplinary talent by investing in training programs that bridge computational, molecular, and engineering skill sets; fostering internal centers of excellence will accelerate the integration of design automation and lab execution. Fifth, pursue targeted partnerships and platform bundling with complementary vendors to deliver turnkey solutions for customers, thereby lowering adoption barriers and creating recurring revenue opportunities. Finally, embed scenario planning and stress-testing into strategic processes to prepare for policy shifts, supply disruptions, and rapid technology changes. Leaders who combine operational resilience, ethical governance, and focused commercialization pathways will capture the most enduring advantages.

A transparent, mixed-methods research approach combining interviews, technical literature, and scenario analysis to produce actionable and validated insights for decision-makers

The research underpinning this summary employed a mixed-methods approach designed to triangulate qualitative insight with quantitative validation, emphasizing reproducibility and transparency. Primary research included structured interviews with executives, R&D leaders, and procurement specialists across instrument manufacturers, reagent suppliers, service providers, and end-user organizations. These conversations provided context on adoption drivers, procurement cycles, and the commercial implications of recent policy shifts. Secondary research incorporated peer-reviewed scientific literature, regulatory guidance, and technical white papers to ground technological descriptions and to ensure accuracy in portraying method capabilities and limitations.

Analytical methods combined thematic analysis of interview data with comparative technology mapping to identify capability clusters and adoption pathways. Supply chain and tariff impact assessments were informed by scenario analysis and procurement case studies that illustrate potential operational responses without relying on a single forecast. Throughout, quality controls included cross-validation of claims against multiple independent sources and review cycles with subject-matter experts to ensure factual accuracy and to correct technical nuance. The methodology focused on delivering insight that is both actionable and defensible, enabling leaders to make informed decisions about investment, partnerships, and operational resilience.

A conclusive synthesis underscoring the critical need to combine platform capability, resilient operations, and ethical governance to translate scientific potential into enduring commercial value

In conclusion, synthetic biology stands at an inflection point where technological convergence, evolving policy environments, and shifting commercial models create both significant opportunity and distinct risk. Organizations that adopt modular automation, cultivate interoperable software and data practices, and develop resilient supply chains will be better positioned to translate scientific innovation into sustainable commercial outcomes. Moreover, those that proactively address governance, ethical concerns, and public transparency will reduce friction in regulatory pathways and strengthen stakeholder trust.

The cumulative effect of these dynamics is a marketplace where competitive advantage accrues to entities that can coordinate platform capabilities, talent, and go-to-market execution while remaining adaptable to policy and supply-chain variability. Strategic clarity-rooted in rigorous segmentation, regional awareness, and a commitment to operational excellence-will separate leaders from followers. For any organization engaging with synthetic biology, the imperative is to act deliberately: align internal capabilities with external partnerships, stress-test assumptions under multiple scenarios, and embed ethical governance as a core business practice to sustain long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of programmable cell therapies leveraging CRISPR-based gene circuits to target solid tumors
  • 5.2. Scaling up microbial fermentation for sustainable production of high-value bio-based chemicals at industrial scale
  • 5.3. Integration of AI-driven design and machine learning for accelerated biosynthetic pathway optimization in microbes
  • 5.4. Adoption of cell-free synthetic biology platforms for rapid prototyping and on-demand biomanufacturing of therapeutics
  • 5.5. Advancements in modular protein scaffolding for precise enzyme colocalization in metabolic engineering
  • 5.6. Regulatory landscape evolution for synthetic biology products enabling faster approvals across major markets
  • 5.7. Investment surge in biocontainment strategies to address safety concerns for environmental release of engineered organisms
  • 5.8. Commercialization of synthetic biology derived cultured meat products with improved texture and cost competitiveness
  • 5.9. Development of biofoundries integrating robotics and high throughput analytics for automated strain engineering workflows
  • 5.10. Emergence of synthetic minimal cells as versatile chassis for custom biosensing and environmental remediation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Biology Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Proteins
    • 8.1.2. Kits & Assays
    • 8.1.3. Media & Supplements
  • 8.2. Instruments
    • 8.2.1. Bioinformatics Workstations
    • 8.2.2. PCR Machines
    • 8.2.3. Sequencers
    • 8.2.4. Synthesizers
  • 8.3. Services
  • 8.4. Software

9. Synthetic Biology Market, by Technology

  • 9.1. Bioinformatics Tools
    • 9.1.1. Data Management
    • 9.1.2. Design Automation
    • 9.1.3. Sequence Analysis
  • 9.2. Cell Engineering
    • 9.2.1. Cell Line Development
    • 9.2.2. Synthetic Cell Design
  • 9.3. Gene Synthesis
    • 9.3.1. DNA Printing
    • 9.3.2. Gene Assembly
    • 9.3.3. Oligonucleotide Synthesis
  • 9.4. Genome Editing
    • 9.4.1. CRISPR Cas
    • 9.4.2. Meganucleases
  • 9.5. Synthetic Genomics
    • 9.5.1. Minimal Cell
    • 9.5.2. Xenobiology

10. Synthetic Biology Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Genetically Modified Crops
    • 10.1.2. Synthetic Fertilizers
  • 10.2. Environmental
    • 10.2.1. Bioremediation
    • 10.2.2. Carbon Capture
    • 10.2.3. Waste Treatment
  • 10.3. Industrial
    • 10.3.1. Biocatalysts
    • 10.3.2. Biofuels
    • 10.3.3. Bioplastics & Biopolymers
    • 10.3.4. Specialty Chemicals
  • 10.4. Life Sciences
    • 10.4.1. Drug Discovery
    • 10.4.2. Gene Therapy
    • 10.4.3. Personalized Medicine
    • 10.4.4. Vaccine Development

11. Synthetic Biology Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Agriculture & Food Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Synthetic Biology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Biology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Biology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Agilent Technologies, Inc.
    • 15.3.2. Illumina, Inc.
    • 15.3.3. Amyris, Inc.
    • 15.3.4. Arzeda
    • 15.3.5. Batavia Biosciences B.V.
    • 15.3.6. Beam Therapeutics
    • 15.3.7. Beckman Coulter, Inc. by Danaher Corporation
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Codexis, Inc.
    • 15.3.10. Conagen, Inc.
    • 15.3.11. Creative Enzymes
    • 15.3.12. DNA TwoPointO Inc.
    • 15.3.13. Editas Medicine, Inc.
    • 15.3.14. Eurofins Scientific SE
    • 15.3.15. GenScript Biotech Corporation
    • 15.3.16. Ginkgo Bioworks, Inc.
    • 15.3.17. Integrated DNA Technologies, Inc.
    • 15.3.18. Merck KGaA
    • 15.3.19. New England Biolabs GmbH
    • 15.3.20. Novozymes A/S
    • 15.3.21. Precigen, Inc.
    • 15.3.22. QIAGEN N.V.
    • 15.3.23. Sangamo Therapeutics
    • 15.3.24. Scarab Genomics, LLC
    • 15.3.25. Synlogic
    • 15.3.26. Synthego Corporation
    • 15.3.27. TeselaGen Service
    • 15.3.28. Thermo Fisher Scientific Inc.
    • 15.3.29. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SYNTHETIC BIOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SYNTHETIC BIOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SYNTHETIC BIOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. G